Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Wed, 08th Dec 2021 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Rockhopper Exploration PLC, up 22% at 6.38 pence, 12-month range 4.50p-12.50p. The oil & gas exploration and production company says Navitas Petroleum LP is to enter its Sea Lion oil project in the Falkland Islands. Navitas replaces Harbour Energy PLC as Rockhopper's partner in the project.

----------

Equals Group PLC, up 12% at 70.40p, 12-month range 26.10p-73.00. The fintech payments firm says it has "significantly exceeded" its full-year expectations for both adjusted earnings and revenue. Group revenue for the year to date is GBP40.4 million, up 51% from GBP26.8 million for the same period in 2020. The strong revenue performance means increased gross profit and earnings, and Equals says it has exceeded its own full-year profitability forecasts, but does not provide a figure.

----------

Clinigen Group PLC, up 10% at 901.00p, 12-month range 541.50p-912.00p. Shares hit 12-month high after the pharmaceuticals and services provider agrees to be taken private by European investment firm Triton Funds in a GBP1.2 billion deal. Under the terms, Clinigen shareholders will receive 883p a share in cash. This is a 41% premium to the ex-dividend closing share price on December 1, which was the last business day before takeover talks were first announced. Clinigen shareholders will also be entitled to receive the previously declared final dividend of 5.46p a share.

----------

AIM - LOSERS

----------

Byotrol PLC, down 16% at 4.22p, 12-month range 4.00p-7.70p. Shares in the antimicrobial technologies company hit fresh 12-month low after profit warning and says its first half performance was below expectations. For six months to September 30, swings to pretax loss of GBP141,000 from GBP1.0 million profit year before. "Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture. At present we are expecting IP sales to offset the majority of the anticipated shortfall in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2016 11:25

Clinigen's Idis Starts Managed Access Programme For Horizon's Ravicti

Read more
14 Jun 2016 07:50

Clinigen's Idis Signs Access Deal For Galen Chemotherapy Drug

Read more
9 Jun 2016 07:40

Clinigen And Basilea To Run Managed Access Programme For Isavuconazole

Read more
10 May 2016 11:09

Clinigen Inks Deal With Cumberland Pharmaceuticals For Ethyol

Read more
5 May 2016 08:42

Clinigen Buys Rights To Bag Presentation Of Foscavir Treatment

Read more
1 Apr 2016 15:01

Dividends Calendar - Week Ahead

Read more
2 Mar 2016 09:31

Clinigen Trading In Line, Buys Totect Drug As First Half Profit Falls

Read more
24 Feb 2016 16:02

Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Jan 2016 09:23

Clinigen Group's acquisitions boost first half growth

(ShareCast News) - Clinigen Group says it has had a solid first half performance, driven by acquisitions and organic growth. The AIM-listed company issued a trading update for the six months to 31 December on Tuesday. It said revenue had risen 116% and it had doubled its gross profit from last year

Read more
19 Jan 2016 07:47

Clinigen First Half Solid With Revenue And Profit Up On Acquisitions

Read more
12 Jan 2016 16:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Dec 2015 09:46

BROKER RATINGS SUMMARY: Berenberg Upgrades Meggitt To Buy From Hold

Read more
3 Dec 2015 12:14

Clinigen Signs Managed Access Programme With Sunesis For Vosaroxin

Read more
30 Nov 2015 08:50

Clinigen Starts Managed Access Programme For Takeda's Ixazomib

Read more
24 Nov 2015 09:22

Clinigen Secures Two-Year Renewal On Accord Healthcare Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.